The group's principal activity is to provide molecular imaging services to the healthcare industry. Mi is a diagnostic procedure used to diagonise, monitor and assess disease severity for many cancers, cardiovascular disease and neurological disorders. The group also provides combined imaging services through mi/ct systems which improves the time to diagnosis, staging of many cancers, cardiovascular disease and neurological disorders and is also used to observe patient response to treatment. The group provides services to hospitals, physician groups, diagnostic imaging centres and other healthcare providers in selected marketplaces in the United States.
